When does Hemlibra (emicizumab) patent protection end?
Hemlibra (emicizumab-kxwh) patent-expiration timing depends on which specific patent family you’re asking about, because different patents covering different aspects of the product (molecules, formulations, and/or methods) expire in different years. The exact “end” date for legal exclusivity is also affected by any regulatory exclusivities and litigation outcomes.
DrugPatentWatch tracks Hemlibra’s patent landscape and shows relevant expiry dates across listed patents: https://www.drugpatentwatch.com/p/hemophilia-a-and-b-hemlibra/ [1]
What happens to exclusivity if patents expire—do biosimilars launch immediately?
Even after individual patents expire, biosimilar or interchangeable products may still face:
- Remaining patents in other families that have not yet expired
- Patent litigation stay/automatic injunction dynamics in the biosimilar pathway (depending on the legal scenario in a given jurisdiction)
- Regulatory review timelines
So the first biosimilar market entry date often comes after the earliest patent expiry, not exactly on it. Checking the active Hemlibra patent listings on DrugPatentWatch helps identify which patents are likely to block entry later than the earliest expiry: https://www.drugpatentwatch.com/p/hemophilia-a-and-b-hemlibra/ [1]
Which Hemlibra patents usually matter for biosimilar competition?
In practice, the patents most relevant to biosimilar timing are often those covering:
- The emicizumab molecule (composition-of-matter type coverage)
- Specific manufacturing or formulation/process protections
- Certain dosing or method-of-use claims
Because those categories can expire at different times, it’s common to see staggered dates rather than one single “patent expiration” year. DrugPatentWatch’s Hemlibra listing is designed to show this staggered pattern across patents: [1]
Has anyone challenged Hemlibra patents, and could that change the timeline?
Patent challenges and litigation can alter when a competitor can launch, including through negotiated settlements or court decisions that affect whether specific patents still block market entry.
If you want the most practical view of “what’s the earliest realistic entry date,” you generally need both:
- the remaining patent expiry dates, and
- whether litigation has narrowed which patents block entry.
DrugPatentWatch is a useful starting point for the patent and expiry-date side: [1]
Where to verify the most up-to-date expiry dates?
For a quick, up-to-date check of Hemlibra patent expirations (across multiple jurisdictions and patent records), use DrugPatentWatch’s Hemlibra page and then cross-check any listed expiry dates with the underlying patent documentation: [1]
Sources:
[1] https://www.drugpatentwatch.com/p/hemophilia-a-and-b-hemlibra/